Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Pacific Biosciences

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

Omnicell

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities across the nation. Its workforce solutions include managed services programs and recruitment process outsourcing. It operates through the following segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment includes travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The Physician and Leadership Solutions segment offers locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The Technology and Workforce Solutions segment focuses on language interpretation, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. The company was founded on November 10, 1997 and is headquartered in Dallas, TX.

AMN Healthcare

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

R1 RCM

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

LabCorp

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

DexCom

ResMed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina

Privia Health Group, Inc. engages in the provision of healthcare services. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experience, and reward doctors for delivering care both in-person and via its Privia Platform, virtual care settings. The company was founded by Jeffrey Butler on November 7, 2007 and is headquartered in Arlington, VA.

Privia Health Group

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Teladoc Health

This sector includes biotechnology, pharmaceuticals, research services, retailers, hospitals, long-term-care facilities, and medical equipment. It also includes companies that provide health information services.

Healthcare

This sector includes companies that manufacture food, beverages, household and personal products, packaging or tobacco. It can also include companies that provide education and training services.

Consumer Defensive

EDOC tracks a market-cap weighted index of companies in the global health care industry with high exposure to telemedicine & digital health.

All investments involve risks, including the loss of principal. Performance data represents past performance and is no guarantee of future results. Investment returns and principal value will fluctuate and are subject to market volatility. An investment, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Full disclosure

__Performance data represents past performance and is no guarantee of future results. Investment returns and principal value will fluctuate and are subject to market volatility. An investment, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted.__

__Investors should consider the investment objectives, risks, and charges and expenses of any Exchange Traded Product (ETP), including any Exchange-Traded Fund (ETF) and any Exchange-Traded Notes (ETNs), carefully before investing. The prospectus and, if available, the summary prospectus contain this and other information about the ETP and should be read carefully before investing. For a current prospectus, please click on the Prospectus link above.__

ETPs that are designed to provide investment results that generally correspond to the performance of their respective underlying indices may not be able to exactly replicate the performance of the indices because of expenses and other factors. ETP shares are bought and sold at market price, which may be higher or lower than their NAV. ETPs are required to distribute portfolio gains to shareholders at year end. These gains may be generated by portfolio rebalancing or the need to meet diversification requirements. ETNs are subject to the credit risk of the underlying issuer. If the issuer defaults on the note, investors may lose some or all of their investment. ETP trading will also generate tax consequences. Additional regulatory guidance on Exchange Traded Products can be found at the [SEC website](https://www.sec.gov/investor/alerts/etfs.pdf) and at the FINRA website ([here](https://www.finra.org/investors/learn-to-invest/types-investments/investment-funds/exchange-traded-fund) and [here](https://www.finra.org/investors/alerts/exchange-traded-notes-avoid-unpleasant-surprises)).

Leveraged and inverse ETPs may involve greater risk and not be suitable for all investors, particularly for buy-and-hold investors. Volatility linked ETPs pose special risks tied to market volatility that can significantly impact the pricing of the product and your ability to trade them during times of extreme market volatility. These types of ETPs generally reset daily and are not designed to, and will not necessarily, track the underlying index or benchmark over a longer period of time. Investing in such ETPs may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. 

The __net asset value (NAV)__ for a fund is calculated by dividing the total net assets of the fund by the total number of shares. NAVs are provided by the fund. ETP investors purchase shares on an exchange at the market price, which may be different from the NAV.

The __expense ratio__ reflects the amount of money a fund charges every year for management, administration, and marketing - expressed as a percentage of total net assets. It does not include any fee waiver or expense reimbursement agreements that may be in effect.

The __30-day yield__ is based on a formula mandated by the Securities and Exchange Commission (SEC) that calculates a fund's hypothetical annualized income, as a percentage of its assets. A security's income, for the purposes of this calculation, is based on the current market yield to maturity (in the case of bonds) or projected dividend yield (for stocks) of the fund's holdings over a trailing 30 day period. This hypothetical income will differ (at times, significantly) from the fund's actual experience; as a result, income distributions from the fund may be higher or lower than implied by the SEC yield.

The market price used to calculate the Price return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the fund are listed for trading, as of the time that the fund’s NAV is calculated. If you trade your shares at another time, your return may differ.

Options trading entails significant risk and is not appropriate for all investors. Options transactions are often complex and may involve the potential of losing your entire investment. Investors should consider their investment objectives and risks carefully before investing in options. To learn more about the risks associated with options, please read the [Characteristics and Risks of Standardized Options](https://cdn.robinhood.com/assets/robinhood/legal/Characteristics%20and%20Risks%20of%20Standardized%20Options.pdf) before you begin trading options. Supporting documentation for any claims, if applicable, will be furnished upon request. 

Commission-free trading refers to $0 commissions for Robinhood Financial self-directed individual cash or margin brokerage accounts that trade U.S. listed and certain OTC securities electronically. Keep in mind, other fees such as trading (non-commission) fees, Gold subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Robinhood Financial’s [fee schedule](https://cdn.robinhood.com/assets/robinhood/legal/RHF%20Fee%20Schedule.pdf) to learn more.

The line chart allows you to select different time spans ranging from 1 day to 5 years and each time span plots a time interval. The 1 day span and weekly spans, there is additional logic to only show the interval when trades occur. This allows you to see when trading volume occurs during periods of slower activity like extended hours or thinly traded equities. The candlestick chart works in the same manner.

Certain fundamental, market data, or other information is provided directly or indirectly by, or based on information provided by, third party data providers, which may include FactSet Research Systems, Inc. (Copyright © 2021 FactSet Research Systems Inc. All rights reserved.), Xignite (xignite.com), ICE Data Services, Morningstar, Inc. (Copyright © 2021 Morningstar. All rights reserved.), and/or other third party providers. Robinhood does not make any warranty or guarantee relating to the accuracy, timeliness or completeness of any third-party information. Any Morningstar information (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely; neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. The provision of this information does not constitute investment advice or a recommendation of any security, transaction, account type, investment strategy involving securities, or order.

Lists may be generated using a combination of data from Morningstar Research Services, LLC, Morningstar, Inc. and/or FactSet Research Systems Inc. and/or their content providers and public filing information from the U.S. Securities and Exchange Commission EDGAR database. Information may not be current. ©2021 Morningstar.  © 2021 FactSet Research Systems Inc. All Rights Reserved. Lists are provided for informational purposes only by Robinhood Markets, Inc., and are not investment advice or a recommendation of any security, transaction, account type, investment strategy involving securities, or order. Robinhood Lists are not personalized recommendations, and the securities listed may not be suitable for you. You should not buy or sell any security on a Robinhood List without first determining it is appropriate for your portfolio or investment strategy.

All investments involve risks, including the loss of principal. Past performance is no guarantee of future results. Securities trading offered through Robinhood Financial LLC, [Member SIPC](https://www.sipc.org/), a registered broker-dealer, and a subsidiary of Robinhood Markets, Inc.

Global X Funds Global X Telemedicine & Digital Health ETF

Why Robinhood?

About EDOC

EDOC tracks a market-cap weighted index of companies in the global health care industry with high exposure to telemedicine & digital health.

What's in this fund

Sectors

Top 10 Holdings (42.42% of total assets)

EDOC Key Statistics

Average Annual Return